---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-264693"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:33:03.954876+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q3 revenue $19.6M, net loss $31.7M; restructuring targets $40M savings

## Summary
- Revenue from continuing ops $19.6M, down 11% YoY; net loss $31.7M vs $21.9M loss in Q3 2024.
- Adjusted EBITDA loss $16.5M vs $13.7M loss; restructuring plan cuts ~20% workforce for $40M annual savings.
- Cash $217M at Sept 30; expects ~$550M cash at close of Illumina transaction in H1 2026.
- FY2025 revenue guidance reaffirmed: combined $165-175M, continuing ops $78-83M.
- Gross margin 48.5% (GAAP) and 53.5% (non-GAAP), down from prior year due to volume and mix.

## SEC filing metadata
- accession: 0001193125-25-264693
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000119312525264693/0001193125-25-264693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000119312525264693/lab-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-264693
- JSON: https://secwatch.observer/filing/0001193125-25-264693.json
- Plain text: https://secwatch.observer/filing/0001193125-25-264693.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.